Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Down 31.3% in February

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the target of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 96,000 shares, a drop of 31.3% from the February 13th total of 139,800 shares. Based on an average daily trading volume, of 309,400 shares, the days-to-cover ratio is presently 0.3 days. Approximately 2.1% of the shares of the company are sold short.

Entero Therapeutics Trading Up 5.4 %

Shares of NASDAQ:ENTO traded up $0.03 during midday trading on Monday, hitting $0.51. The company’s stock had a trading volume of 77,602 shares, compared to its average volume of 395,784. The stock’s 50 day simple moving average is $0.53 and its 200 day simple moving average is $0.52. Entero Therapeutics has a fifty-two week low of $0.19 and a fifty-two week high of $3.16.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.